Sabatowski R, Arens E R, Waap I, Radbruch L
Klinik und Poliklinik für Anästhesiologie und Operative Intensivmedizin, Universität zu Köln.
Schmerz. 2001 Aug;15(4):241-7. doi: 10.1007/s004820100054.
The German regulations for opioid prescriptions have been changed in February 1998. The regulations have been made much more easier and should therefore have improved the pain management in Germany. We investigated the knowledge of the WHO analgesic ladder and how they have been followed in a nation-wide survey among physicians not specialised in pain management. Only 9% of the questionnaires were returned. Although the majority of the physicians (93%) reported knowledge about the WHO recommendations for the treatment of cancer pain, more than 15% of the participating physicians rated transdermal fentanyl as a weak opioid or even as a non-opioid. A negative pain management index in 15% of the patients gave evidence of poor quality in pain management. The majority of patients (84%) did not receive immediate release analgesics for the treatment of breakthrough pain. Continuous medical education is still necessary before a further alleviation of regulations will help to reduce the undertreatment of patients suffering from cancer pain in Germany.
德国的阿片类药物处方规定于1998年2月进行了修订。规定变得更加宽松,因此应该改善了德国的疼痛管理状况。我们在一项针对非疼痛管理专科医生的全国性调查中,研究了他们对世界卫生组织(WHO)镇痛阶梯的了解情况以及遵循程度。仅9%的问卷被收回。尽管大多数医生(93%)报告了解WHO关于癌症疼痛治疗的建议,但超过15%的参与医生将透皮芬太尼评定为弱阿片类药物甚至非阿片类药物。15%的患者疼痛管理指数为负,证明疼痛管理质量较差。大多数患者(84%)在治疗爆发性疼痛时未接受即释镇痛药。在进一步放宽规定有助于减少德国癌症疼痛患者治疗不足的情况之前,持续医学教育仍然是必要的。